日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Comparison of Clinical Characteristics and Mortality Outcome in Critical COVID-19 Patients Infected with Alpha and Omicron Variants

比较感染α和Omicron变异株的COVID-19重症患者的临床特征和死亡结局

Cheng, Hsin-I; Chang, Ko-Wei; Wu, Bing-Chen; Teo, Mei-Yuan; Hung, Wei-Syun; Wu, Hao-Ming; Huang, Allen Chung-Cheng; Lin, Chang-Wei; Lin, Ting-Yu; Lin, Horng-Chyuan; Chiu, Cheng-Hsun; Lin, Shu-Min

Clinical outcome analysis of different first‑ and second‑generation EGFR‑tyrosine kinase inhibitors in untreated patients with EGFR‑mutated non‑small cell lung cancer with baseline brain metastasis.

对未经治疗的 EGFR 突变非小细胞肺癌伴基线脑转移患者进行不同的第一代和第二代 EGFR 酪氨酸激酶抑制剂的临床结果分析

Hsu Chen-Chuan, Chiu Li-Chung, Ko How-Wen, Wu Chiao-En, Kuo Scott Chih-Hsi, Ju Jia-Shiuan, Huang Allen Chung-Cheng, Wang Chin-Chou, Yang Cheng-Ta, Hsu Ping-Chih

Single-Cell RNA-Seq Reveals Adventitial Fibroblast Alterations during Mouse Atherosclerosis

单细胞 RNA 测序揭示小鼠动脉粥样硬化期间外膜成纤维细胞的改变

Lauren E Fries, Allen Chung, Hyun K Chang, Timothy L Yuan, Robert C Bauer

Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC

EGFR TKI治疗的晚期非小细胞肺癌中肿瘤和血浆T790M突变的差异性预后价值

Tung, Pi-Hung; Chiu, Tzu-Hsuan; Huang, Allen Chung-Cheng; Ju, Jia-Shiuan; Huang, Chi-Hsien; Wang, Chin-Chou; Ko, How-Wen; Chung, Fu-Tsai; Hsu, Ping-Chih; Fang, Yueh-Fu; Guo, Yi-Ke; Kuo, Chih-Hsi Scott; Yang, Cheng-Ta

A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

抗程序性死亡配体1 (PD-L1) 免疫检查点抑制剂联合化疗治疗未经治疗的广泛期小细胞肺癌的临床分析

Hsu, Ping-Chih; Wu, Bing-Chen; Wang, Chin-Chou; Chiu, Li-Chung; Chang, Chiung-Hsin; Liu, Ping-Chi; Wu, Chiao-En; Kuo, Scott Chih-Hsi; Ju, Jia-Shiuan; Huang, Allen Chung-Cheng; Lin, Yu-Ching; Yang, Cheng-Ta; Ko, How-Wen

Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer

一线阿法替尼治疗晚期表皮生长因子受体突变型非小细胞肺癌患者延长无进展生存期的相关因素

Chiu, Li-Chung; Hsu, Ping-Chih; Wang, Chin-Chou; Ko, How-Wen; Kuo, Scott Chih-Hsi; Ju, Jia-Shiuan; Tung, Pi-Hung; Huang, Allen Chung-Cheng; Yang, Cheng-Ta

Clinical and laboratory predictors for disease progression in patients with COVID-19: A multi-center cohort study

COVID-19患者疾病进展的临床和实验室预测指标:一项多中心队列研究

Lin, Shu-Min; Huang, Allen Chung-Cheng; Chiu, Tzu-Hsuan; Chang, Ko-Wei; Huang, Tse-Hung; Yang, Tsung-Hsien; Shiao, Yi-Hsien; Lee, Chung-Shu; Chung, Fu-Tsai; Chen, Chyi-Liang; Chiu, Cheng-Hsun

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan

阿法替尼治疗未经治疗的伴有主要罕见表皮生长因子受体 (EGFR) 突变 (G719X/L861Q/S768I) 的 IIIB/IV 期肺腺癌:一项台湾多中心观察性研究

Hsu, Ping-Chih; Lee, Suey-Haur; Chiu, Li-Chung; Lee, Chung-Shu; Wu, Chiao-En; Kuo, Scott Chih-Hsi; Ju, Jia-Shiuan; Huang, Allen Chung-Cheng; Li, Shih-Hong; Ko, Ho-Wen; Yang, Cheng-Ta; Wang, Chin-Chou

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors

对于接受一线贝伐珠单抗联合第一/二代EGFR酪氨酸激酶抑制剂治疗的晚期表皮生长因子受体突变肺腺癌患者,序贯治疗方案

Hsu, Ping-Chih; Huang, Chun-Yao; Lin, Yu-Ching; Lee, Suey-Haur; Chiu, Li-Chung; Wu, Chiao-En; Kuo, Scott Chih-Hsi; Ju, Jia-Shiuan; Huang, Allen Chung-Cheng; Ko, Ho-Wen; Wang, Chin-Chou; Yang, Cheng-Ta

High-Dimensional Single-Cell Multimodal Landscape of Human Carotid Atherosclerosis

人类颈动脉粥样硬化的高维单细胞多模态景观

Alexander C Bashore, Hanying Yan, Chenyi Xue, Lucie Y Zhu, Eunyoung Kim, Thomas Mawson, Johana Coronel, Allen Chung, Sebastian Ho, Leila S Ross, Michael Kissner, Emmanuelle Passegué, Robert C Bauer, Lars Maegdefessel, Mingyao Li, Muredach P Reilly